Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver

Hepatology

Volumn 52, Issue 5, 2010, Pages 1758-1768

  Denk, Gerald U ^a   Maitz, Silvia ^a,b   Wimmer, Ralf ^a   Rust, Christian ^a   Invernizzi, Pietro ^b   Ferdinandusse, Sacha ^c   Kulik, Wim ^c   Fuchsbichler, Andrea ^d   Fickert, Peter ^d   Trauner, Michael ^d   Hofmann, Alan F ^e   Beuers, Ulrich ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENYL S GLUTATHIONE; BILE ACID; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 2; NORURSODEOXYCHOLIC ACID; TAURINE NORURSODEOXYCHOLIC ACID; TAUROLITHOCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE FLOW; CELL STRAIN HEPG2; CHOLESTASIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; ENZYME RELEASE; GAS CHROMATOGRAPHY; GENETIC TRANSFECTION; GRAVIMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; ISOLATED LIVER; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECTROPHOTOMETRY; TANDEM MASS SPECTROMETRY;

ANIMALS; APOPTOSIS; BILE; BILE ACIDS AND SALTS; CARCINOMA, HEPATOCELLULAR; CHOLANGITIS; CHOLESTASIS; CHROMATOGRAPHY, GAS; HEPATOBLASTOMA; HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; TAURINE; TAUROLITHOCHOLIC ACID; URSODEOXYCHOLIC ACID;

EID: 78049492335     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23911     Document Type: Article

References (39)

1. Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. HEPATOLOGY 1990; 12: 1216-1221.
2. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303.
3. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-720.
4. Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. HEPATOLOGY 2008; 48: 871-877.
5. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-1287.
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
7. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-328.
8. Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. HEPATOLOGY 2005; 42: 1391-1398.
9. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-481.
10. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. HEPATOLOGY 2009; 49: 1972-1981.
11. Wimmer R, Hohenester S, Pusl T, Denk GU, Rust C, Beuers U. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut 2008; 57: 1448-1454.
12. Javitt J. Cholestasis in rats induced by taurolithocholate. Nature 1966; 210: 1262-1263.
13. Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. HEPATOLOGY 2001; 33: 1206-1216.
14. Beuers U, Denk GU, Soroka CJ, Wimmer R, Rust C, Paumgartner G, et al. Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. J Biol Chem 2003; 278: 17810-17818.
15. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 2006; 168: 410-422.
16. Dombrowski F, Stieger B, Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 2006; 86: 166-174.
17. Beuers U, Probst I, Soroka C, Boyer JL, Kullak-Ublick GA, Paumgartner G. Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes. HEPATOLOGY 1999; 29: 477-482.
18. Rust C, Wild N, Bernt C, Vennegeerts T, Wimmer R, Beuers U. Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem 2009; 284: 2908-2916.
19. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001; 35: 134-146.
20. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790-2799.
21. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. HEPATOLOGY 2004; 39: 1563-1573.
22. Tserng KY, Hachey DL, Klein PD. An improved procedure for the synthesis of glycine and taurine conjugates of bile acids. J Lipid Res 1977; 18: 404-407.
23. ++ mechanisms defective in cholestasis. J Clin Invest 1993; 92: 2984-2993.
24. Wahllander A, Sies H. Glutathione S-conjugate formation from 1-chloro-2, 4-dinitrobenzene and biliary S-conjugate excretion in the perfused rat liver. Eur J Biochem 1979; 96: 441-446.
25. Rust C, Bauchmuller K, Bernt C, Vennegeerts T, Fickert P, Fuchsbichler A, et al. Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers. Gut 2006; 55: 719-727.
26. Stellaard F, Sackmann M, Sauerbruch T, Paumgartner G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res 1984; 25: 1313-1319.
27. Ferdinandusse S, Denis S, Overmars H, Van Eeckhoudt L, Van Veldhoven PP, Duran M, et al. Developmental changes of bile acid composition and conjugation in L- and D-bifunctional protein single and double knockout mice. J Biol Chem 2005; 280: 18658-18666.
28. Bergmeyer HU, Bernt E. Lactate dehydrogenase In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. Volume 3. New York: Academic Press; 1983: 574-579.
29. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238-1251.
30. +-taurocholate cotransporting green fluorescent protein in human hepatoblastoma HepG2 cells. Cytotechnology 2000; 34: 1-9.
31. Denk GU, Hohenester S, Wimmer R, Bohland C, Rust C, Beuers U. Role of mitogen-activated protein kinases in tauroursodeoxycholic acid-induced bile formation in cholestatic rat liver. Hepatol Res 2008; 38: 717-726.
32. Van Nieuwkerk CM, Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, et al. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996; 111: 165-171.
33. Cohen BI, Hofmann AF, Mosbach EH, Stenger RJ, Rothschild MA, Hagey LR, et al. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology 1986; 91: 189-197.
34. Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986; 90: 837-852.
35. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, et al. Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am J Physiol Gastrointest Liver Physiol 2006; 290: G550-G556.
36. Nathanson MH, Burgstahler AD, Masyuk A, Larusso NF. Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem J 2001; 358: 1-5.
37. Fiorotto R, Spirli C, Fabris L, Cadamuro M, Okolicsanyi L, Strazzabosco M. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007; 133: 1603-1613.
38. 3 umbrella. HEPATOLOGY 2010; doi: 10.1002/hep.23810.
39. Holsti P. Experimental cirrhosis of the liver in rabbits induced by gastric instillation of desiccated whole bile. Acta Pathol Microbiol Scand Suppl 1956; 39: 1-66.